Cart
sales@molnova.com
DHODH-IN-23
CAS No. 1346705-53-0
DHODH-IN-23( —— )
Catalog No. M36042 CAS No. 1346705-53-0
DHODH-IN-23 is a DHODH inhibitor with oral activity. DHODH-IN-23 is often used in cancer research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 46 | In Stock |
|
| 10MG | 72 | In Stock |
|
| 25MG | 164 | In Stock |
|
| 50MG | 254 | In Stock |
|
| 100MG | 367 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDHODH-IN-23
-
NoteResearch use only, not for human use.
-
Brief DescriptionDHODH-IN-23 is a DHODH inhibitor with oral activity. DHODH-IN-23 is often used in cancer research.
-
DescriptionDHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer.
-
In VitroCell Proliferation Assay Cell Line:U937, HL-60, THP-1, KG-1 and MV411 Concentration:Incubation Time:72 h Result:Inhibited cell growth with GI50s of 2.4, 2.5, 2.5, 3.5 and 7.6 μM against U937, THP-1, MV411 HL-60 and KG-1, respectively.RT-PCR Cell Line:THP-1 cells Concentration:72 h Incubation Time:0.1, 1 and 3 μM Result:Induced CDllb mRNA expression.
-
In VivoAnimal Model:MV411 mouse xenograft model Dosage:30 mg/kg Administration:Oral administration, twice daily for 21 days Result:Demonstrated significant anti-tumor activity both as a single agent and in combination with Cytarabine (HY-13605) at 20 mg/kg with tumor growth inhibitions of 37 and 73% respectively.
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetDehydrogenase
-
RecptorDehydrogenase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1346705-53-0
-
Formula Weight441.88
-
Molecular FormulaC24H21ClFNO4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (282.88 mM; Ultrasonic )
-
SMILESClC=1C=C(C=C(F)C1NC(=O)C2=C(C(O)=O)C=CC=C2)C3=CC(OCCCC)=CC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Srikant Viswanadha, et al. Compositions comprising a dhodh inhibitor for the treatment of acute myeloid leukemia. Patent WO2021079273A1.
molnova catalog
related products
-
IGP-1
iGP-1 is a mitochondrial sn-glycerol 3-phosphate dehydrogenase (mGPDH) inhibitor that can be used to study obesity.
-
Mangostin
Mangostin is a natural xanthonoid, a type of organic compound isolated from various parts of the mangosteen tree.
-
IDH2R140Q-IN-2
IDH2R140Q-IN-2 is an orally active and potent IDH2R140Q inhibitor with an IC50 of 29 nM.IDH2R140Q-IN-2 possesses potential antitumour activity, reducing D2HG production in TF-1 cell lines carrying the IDH2R140Q mutation (IC50 of 10 nM) and inhibiting tumour tissue D2HG levels.
